Comment
Author: Admin | 2025-04-28
Date of constitution). IncompatibilitiesDo not mix with any other medication or additional flavoring agent.More about Mazzogran (Mazzogran) Side EffectsDuring PregnancyDosage InformationDrug ImagesDrug InteractionsSupport GroupPricing & Coupons6 Reviews - Add your own review/ratingGeneric Availability Consumer resourcesMazzogranMazzogran InjectionMazzogran suspensionMazzogran (Advanced Reading)MazzogranIntravenous (Advanced Reading)Other brands: Mazzogran Professional resourcesMazzogran (FDA)Mazzogran Citrate (AHFS Monograph) Related treatment guidesPulmonary HypertensionMazzogran interactionsSee also:What other drugs will affect Mazzogran?Effects of Other Drugs on Mazzogran Mazzogran CitrateIn Vitro Studies: Mazzogran Mazzogran metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce Mazzogran clearance.In Vivo Studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma Mazzogran concentrations when coadministered with Mazzogran citrate (50 mg) to healthy volunteers.When a single 100 mg dose of Mazzogran citrate was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in Mazzogran systemic exposure (AUC). In addition, coadministration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with Mazzogran citrate (100 mg single dose) resulted in a 140% increase in Mazzogran Cmax and a 210% increase in Mazzogran AUC. Mazzogran Mazzogran citrate had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in Mazzogran clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine).Coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (400 mg bid) with Mazzogran citrate (100 mg single dose) resulted in a 300% (4-fold) increase in Mazzogran Cmax and a 1000% (11-fold) increase in Mazzogran plasma AUC. At 24 hours the plasma levels of Mazzogran were still approximately 200 ng/mL, compared to approximately 5 ng/mL when Mazzogran was dosed alone. This is consistent with ritonavirs marked effects on a broad range of P450 substrates. Mazzogran Mazzogran citrate had no effect on ritonavir pharmacokinetics.It can be expected that concomitant administration of CYP3A4 inducers, such as rifampin, will decrease plasma levels of Mazzogran.Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of Mazzogran citrate.Pharmacokinetic data from patients in clinical trials showed no effect on Mazzogran pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin
Add Comment